Medication Management for Treatment-Resistant OCD

Primary Recommendations

• The American Academy of Child and Adolescent Psychiatry recommends augmenting the current clomipramine with an atypical antipsychotic, such as aripiprazole 5-10mg or low-dose risperidone 0.5-2mg, for inadequately controlled OCD, while maintaining seizure precautions and continuing lamotrigine for mood stabilization and seizure prophylaxis 1, 2
• Aripiprazole is preferred due to its lower seizure risk and fewer extrapyramidal symptoms compared to other antipsychotics 3, 4

Clinical Considerations

• The combination of clomipramine, lamotrigine, and atypical antipsychotic is supported by guideline principles for treatment-resistant OCD, targeting different mechanisms: serotonergic, glutamatergic, and dopaminergic 1, 2, 6, 8
• The American Academy of Child and Adolescent Psychiatry suggests that stimulants, such as Adderall, do not significantly worsen OCD symptoms in most patients and should be continued for ADHD management 6
• The American Family Physician recommends avoiding medications that lower the seizure threshold, such as bupropion and high-dose antipsychotics, in patients with a history of seizures 5, 7

Monitoring and Next Steps

• The American Academy of Child and Adolescent Psychiatry recommends reassessing Y-BOCS at 8-12 weeks after antipsychotic addition and lamotrigine optimization, and weekly assessment of suicidal ideation 1, 2
• If there is an inadequate response after 12 weeks, consider intensive outpatient or residential OCD treatment programs, and reserve neurosurgery, including deep brain stimulation, for patients who have failed multiple trials 1, 2